

Resolution

of the Federal Joint Committee on an Amendment of the
Pharmaceuticals Directive:

Annex XII – Benefit Assessment of Medicinal Products with
New Active Ingredients according to Section 35a SGB V
Ivacaftor (new therapeutic indication: cystic fibrosis,
combination regimen with Ivacaftor/ Tezacaftor/ Elexacaftor,
6 to 11 years (heterozygous for F508del and RF mutations))

of 4 August 2022

At its session on 4 August 2022, the Federal Joint Committee (G-BA) resolved to amend the
Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009
(Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the
resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

- I. **In Annex XII, the following information shall be added after No. 4 to the information on the benefit assessment of Ivacaftor in accordance with the resolution of 4 August 2022:**

Ivacaftor

Resolution of: 4 August 2022

Entry into force on: 4 August 2022

Federal Gazette, BAnz AT DD. MM YYYY Bx

New therapeutic indication (according to the marketing authorisation of 7 January 2022):

Kalydeco tablets are indicated in a combination regimen with ivacaftor/ tezacaftor/ elexacaftor tablets for the treatment of adults, adolescents and children aged 6 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene.

Therapeutic indication of the resolution (resolution of 4 August 2022):

Kalydeco tablets are indicated in a combination regimen with ivacaftor/ tezacaftor/ elexacaftor tablets for the treatment of children aged 6 to 11 years with cystic fibrosis, who are heterozygous for the F508del mutation in the CFTR gene and carry a residual function mutation on the second allele.

1. Additional benefit of the medicinal product in relation to the appropriate comparator therapy

Children aged 6 to 11 years with cystic fibrosis who are heterozygous for the F508del mutation in the CFTR gene and carry a residual function mutation on the second allele

Appropriate comparator therapy for ivacaftor in combination with Ivacaftor/ Tezacaftor/ Elexacaftor:

tezacaftor/ ivacaftor in combination with ivacaftor

Extent and probability of the additional benefit of Ivacaftor in combination with Ivacaftor/ Tezacaftor/ Elexacaftor compared to the appropriate comparator therapy:

An additional benefit is not proven.

Study results according to endpoints:¹

Children aged 6 to 11 years with cystic fibrosis who are heterozygous for the F508del mutation in the CFTR gene and carry a residual function mutation on the second allele

Summary of results for relevant clinical endpoints

Endpoint category	Direction of effect/ risk of bias	Summary
Mortality	∅	No data available.
Morbidity	∅	No data available.
Health-related quality of life	∅	No data available.
Side effects	∅	No data available.

Explanations:
↑: statistically significant and relevant positive effect with low/unclear reliability of data
↓: statistically significant and relevant negative effect with low/unclear reliability of data
↑↑: statistically significant and relevant positive effect with high reliability of data
↓↓: statistically significant and relevant negative effect with high reliability of data
↔: no statistically significant or relevant difference
∅: There are no usable data for the benefit assessment.
n.a.: not assessable

2. Number of patients or demarcation of patient groups eligible for treatment

Children aged 6 to 11 years with cystic fibrosis who are heterozygous for the F508del mutation in the CFTR gene and carry a residual function mutation on the second allele

approx. 21 patients

3. Requirements for a quality-assured application

The requirements in the product information are to be taken into account. The European Medicines Agency (EMA) provides the contents of the product information (summary of product characteristics, SmPC) for Kalydeco (active ingredient: ivacaftor) at the following publicly accessible link (last access: 19 May 2022):

https://www.ema.europa.eu/en/documents/product-information/kalydeco-epar-product-information_en.pdf

¹ Data from the dossier assessment of the IQWiG (A22-18, A22-24) unless otherwise indicated.

Treatment with ivacaftor should only be initiated and monitored by doctors experienced in the therapy of children with cystic fibrosis.

4. Treatment costs

Annual treatment costs:

Children aged 6 to 11 years with cystic fibrosis who are heterozygous for the F508del mutation in the CFTR gene and carry a residual function mutation on the second allele

Designation of the therapy	Annual treatment costs/ patient
Medicinal product to be assessed:	
Ivacaftor	€ 82,914.18 - € 82,970.63
+ ivacaftor/ tezacaftor/ elexacaftor	€ 156,562.19
Total:	€ 239,476.37 - € 239,532.81
Appropriate comparator therapy:	
Tezacaftor/ elexacaftor	€ 65,035.44
+ ivacaftor	€ 82,914.18 - € 82,970.63
Total:	€ 147,949.62 - € 148,006.07

Costs after deduction of statutory rebates (LAUER-TAXE®) as last revised: 15 July 2022)

Costs for additionally required SHI services: not applicable

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 4 August 2022.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 4 August 2022

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken